CClinicalTrials.gg
CompletedNCT02038686PFN-AUpdated Feb 2, 2017

Treatment of Unstable 31.A2 and 31.A3 Trochanteric Fractures. Randomised Comparison of the Proximal Femoral Nail PFN-A Short and the PFN-A Long.

An interventional study of PFN-A in Unstable Proximal Femoral Fracture, sponsored by Ferran Fillat Gomà. Completed at 1 site in Spain. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2017-02-02.

Sponsored by Ferran Fillat Gomà · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

  1. Introduction:

    Controversy exists with regard to whether to treat AO/OTA (Orthopaedic Trauma Association) 32.A2 - 32-A3 fractures of the proximal part of the femur with an intramedullary short PFN-A or long PFN-A. A prospective, randomized, controlled trial is performed to compare the outcome treatment of these unstable fractures of the proximal part of the femur with either a short PFN-A (170-240mm) or long PFN-A (300-420mm).

  2. Objectives and Hypothesis The hypothesis is that the Short PFN-A would have fewer complications than Long PFN-A

    Main Objective: Is defined as Total number of complications between PFN-A short and PFN-A long. Outcome measures were subdivided into preoperative, perioperative and post-operative. Follow up data at four weeks, three months and one year.

    Secondary objectives: Complete and uneventful radiological and clinical healing of the fracture. Revision operations (related to the failure of primary treatment) and mortality. Baseline characteristics were documented pre-operatively: Outcome measures were subdivided into intra-operative, post-operative and follow up data at four weeks, three months and one year.

  3. Methodology: One hundred and eighty eight patients presenting with an AO/OTA 31-A2 and 31-A3 fracture of the proximal part of the femur will be randomized, at the time of the admission, to fixation with use either a short PFN-A or a long PFN-A.
02

Conditions studied

  • Unstable Proximal Femoral Fracture

Keywords

  • Hip fracture
  • Unstable (31A2 and 31A3)
  • Proximal femoral nail
03

In context

Fractures, Bone

2,261 studies on the registry are indexed under Fractures, Bone; 325 are open to participants now.

This study's enrollment of 188 is above the median of 69 across 1,482 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

This is the only study on the registry with Ferran Fillat Gomà as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients 60 years old above.
  • Patients with trochanteric fracture 31.A2 and 31.A3 AO classification for long bones
  • Patients that accept to participate on the study under consent

Exclusion criteria

Exclusion Criteria:

  • Metaphyseal fractures with extension more than 3 cm in reference to lesser trochanter calibrated and analyzed with PreOPlan registered application.
  • Combination of fractures in the proximal femur.
  • Pathological fractures.
  • Diaphyseal femoral fractures.
  • Rejection of surgery by the patient.
  • Contraindications to the use of either implants studied.
  • Patients who do not wish to participate in this study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
188 participants (actual)

Study arms

  • Active comparator
    Standard PFN-A

    Patients with unstable proximal femoral fractures treated with PFN-A short nail (170-240mm)

    Device: PFN-A

  • Active comparator
    Long PFN-A

    Patients with unstable proximal femoral fractures treated with PFN-A long nail (300-420mm)

    Device: PFN-A

Interventions

  • DevicePFN-A

    Also known as: Proximal femoral nail Synthes

06

What researchers measure

Primary outcomes

  1. Total number of complications between PFN-A short and PFN-A long

    follow-up data is recruited at 4 weeks, 3 months and one

    Time frame: One year

Secondary outcomes

  1. Complete and uneventful radiological and clinical healing of the fracture and mortality

    follow-up data is recruited at 4 weeks, 3 months and one year.

    Time frame: One year

07

Study locations

1 site
  • Hospital Universitario Parc Taulí de Sabadell
    Sabadell, Barcelona 08208, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02038686
Lead sponsor
Ferran Fillat Gomà
Collaborators
Parc Taulí Hospital Universitari
Responsible party
Ferran Fillat Gomà (Medical Doctor, Corporacion Parc Tauli) — Sponsor-investigator
First posted
Jan 16, 2014
Start date
Jan 2014
Primary completion
Jan 2016
Completion
Jan 2017
Last update
Feb 2, 2017

Study contacts

Ferran Fillat-Gomà, MD
principal investigator · Hospital Universitario Parc Tauli de Sabadell
Joan Murias-Álvarez, MD
study director · Hospital Universitario Parc Tauli de Sabadell

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion